Anhui Zhifei Longcom: RBD-Dimer

Anhui Zhifei Longcom: RBD-Dimer

Vaccine Type: Protein Subunit

About Trial Phases

Phase 1: 3 Trials

NCT04550351, ChiCTR2000035691
China
NCT04636333
China
NCT04445194
China

Phase 2: 1 Trial

NCT04466085
China

Phase 3: 1 Trial

ChiCTR2000040153, NCT04646590
China

Approvals: 0 Approvals

This vaccine is not yet approved.

Registered Trials

ChiCTR2000040153, NCT04646590
Phase 3
China
Total Enrollment: 29,000
Official Trial Registration:
- ChiCTR2000040153(Opens in new tab/window)
- NCT04646590(Opens in new tab/window)
NCT04466085
Phase 2
China
Total Enrollment: 900
Official Trial Registration:
- NCT04466085(Opens in new tab/window)
NCT04550351, ChiCTR2000035691
Phase 1
China
Total Enrollment: 50
Official Trial Registration:
- NCT04550351(Opens in new tab/window)
- ChiCTR2000035691(Opens in new tab/window)
NCT04636333
Phase 1
China
Total Enrollment: 216
Official Trial Registration:
- NCT04636333(Opens in new tab/window)
NCT04445194
Phase 1
China
Total Enrollment: 50
Official Trial Registration:
- NCT04445194(Opens in new tab/window)

© 2021 McGill COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form